Hematology Department, University Hospital, Petersgraben 4, Basel, Switzerland.
Expert Rev Hematol. 2009 Oct;2(5):583-601. doi: 10.1586/ehm.09.48.
Hematopoietic stem cell transplantation (HSCT) offers the opportunity for cure to patients with leukemia, lymphoma and severe non-malignant diseases. More than 40,000 HSCTs are performed annually worldwide. Therefore, the number of long-term survivors, free of the disease for which they were transplanted is continuously increasing. Despite the improved prognosis of HSCT, long-term outcome may be impaired by transplant-associated morbidity and mortality. Long-term survivors can present a variety of malignant and non-malignant complications, impairing physical and psychological performance, normal integration in family and social life, and quality of life. Conditioning regimens, particularly when including total-body irradiation as well as graft-versus-host disease, play a key role in the development of late effects. However, with increasing time since transplantation new types of late effects may emerge. Awareness on long-term effects after HSCT is crucial to provide adapted pretransplant counseling, and recommendations for post-transplant screening, prevention and early treatment.
造血干细胞移植(HSCT)为白血病、淋巴瘤和严重非恶性疾病患者提供了治愈的机会。全世界每年进行的 HSCT 超过 40000 例。因此,长期无病生存者的数量,即移植治疗疾病缓解者的数量在不断增加。尽管 HSCT 的预后有所改善,但移植相关发病率和死亡率仍会影响长期预后。长期幸存者可能会出现各种恶性和非恶性并发症,影响身体和心理功能、正常的家庭和社会生活融入以及生活质量。预处理方案,特别是包含全身照射和移植物抗宿主病的方案,在晚期并发症的发展中起着关键作用。然而,随着移植后时间的延长,可能会出现新类型的晚期并发症。了解 HSCT 后的长期影响对于提供适当的移植前咨询以及移植后筛查、预防和早期治疗的建议至关重要。